Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials

Mahmud, Md. Musavvir; Pandey, Nikhil; Winkles, Jeffrey A.; Woodworth, Graeme F.; Kim, Anthony J.

doi:10.1016/j.nantod.2024.102314

Nano Today

2024

DOI: 10.1016/j.nantod.2024.102314

|View full text |Cite

Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials

Md. Musavvir Mahmud,

Nikhil Pandey,

Jeffrey A. Winkles

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Nanomedicine for cancer patient‐centered care

Sorrentino,

Ciummo,

Fieni

et al. 2024

MedComm

View full text Add to dashboard Cite

Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low‐toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient's tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine‐based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Several nanoformulations are currently in clinical trials, and some have been approved and marketed. However, their large‐scale production and use are still hindered by an in‐depth debate involving ethics, intellectual property, safety and health concerns, technical issues, and costs. Here, we survey the key approaches, with specific reference to organ‐on chip technology, and cutting‐edge tools, such as CRISPR/Cas9 genome editing, through which nanosystems can meet the needs for personalized diagnostics and therapy in cancer patients. An update is provided on the nanopharmaceuticals approved and marketed for cancer therapy and those currently undergoing clinical trials. Finally, we discuss the emerging avenues in the field and the challenges to be overcome for the transfer of nano‐based precision oncology into clinical daily life.

show abstract

Nanomedicine for cancer patient‐centered care

Sorrentino,

Ciummo,

Fieni

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Advanced membrane technologies for water treatment: utilization of nanomaterials and nanoparticles in membranes fabrication

Shukla,

Sharma,

Yadav

et al. 2024

J Nanopart Res

View full text Add to dashboard Cite

Hyaluronic Acid in Nanopharmaceuticals: An Overview

Matalqah,

Lafi,

Asha

2024

CIMB

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a naturally occurring, long, unbranched polysaccharide that plays a critical role in maintaining skin structure and hydration. Its unique properties make it a valuable component in the field of nanopharmaceuticals. The combination of HA into nanopharmaceuticals enhances its ability to interact with various therapeutic agents, improving the delivery and efficacy of drugs. HA-based nanoparticles, including solid lipid nanoparticles, and polymeric nanogels, offer controlled release, enhanced stability, and targeted delivery of therapeutic agents. These innovations significantly improve therapeutic outcomes and reduce side effects, making HA an essential tool in modern medicine. In general, HA-modified liposomes enhance drug encapsulation and targeting, while HA-modified solid lipid nanoparticles (SLNs) provide a solid lipid core for drug encapsulation, offering controlled release and stability. This article provides an overview of the potential applications and recent advancements of HA in nanopharmaceuticals, emphasizing its significant impact on the evolving field of targeted drug delivery and advanced therapeutic strategies. By delving into the unique properties of HA and its compatibility with various therapeutic agents, this review underscores the promising potential of HA in revolutionizing nanopharmaceuticals.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials

Cited by 3 publications

References 153 publications

Nanomedicine for cancer patient‐centered care

Nanomedicine for cancer patient‐centered care

Advanced membrane technologies for water treatment: utilization of nanomaterials and nanoparticles in membranes fabrication

Hyaluronic Acid in Nanopharmaceuticals: An Overview

Contact Info

Product

Resources

About